Proteomic profiling predicts drug response to novel targeted anticancer therapeutics. (2nd April 2016)

• Record Type: Journal Article
• Authors: Lin, Fan; Li, Zilin; Hua, Yunfen; Lim, Yoon Pin
• Is Part Of: Expert review of proteomics. Volume 13:Number 4(2016)
• Page Start: 411
• Page End: 420
• Publication Date: 2016-04-02
• Subjects: Proteomic profiling -- targeted drug -- combination therapy -- drug response -- personalized therapy; Proteins -- Biotechnology -- Periodicals; Proteomics -- Periodicals; 572.6
• DOI: 10.1586/14789450.2016.1164043
• Languages: English
• ISSNs: 1478-9450

Abstract

ABSTRACT: Most recently approved anti-cancer drugs by the US FDA are targeted therapeutic agents and this represents an important trend for future anticancer therapy. Unlike conventional chemotherapy that rarely considers individual differences, it is crucial for targeted therapies to identify the beneficial subgroup of patients for the treatment. Currently, genomics and transcriptomics are the major 'omic' analytics used in studies of drug response prediction. However, proteomic profiling excels both in its advantages of directly detecting an instantaneous dynamic of the whole proteome, which contains most current diagnostic markers and therapeutic targets. Moreover, proteomic profiling improves understanding of the mechanism for drug resistance and helps finding optimal combination therapy. This article reviews the recent success of applications of proteomic analytics in predicting the response to targeted anticancer therapeutics, and discusses the potential avenues and pitfalls of proteomic platforms and techniques used most in the field.